| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple Sclerosis
|
Ingwersen, Jens
|
|
2015
|
13 |
1 |
p. 47-57
|
article
|
| 2 |
Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple Sclerosis
|
Ingwersen, Jens
|
|
|
13 |
1 |
p. 47-57
|
article
|
| 3 |
Anti-B-Cell Therapies in Autoimmune Neurological Diseases: Rationale and Efficacy Trials
|
Alexopoulos, Harry
|
|
2015
|
13 |
1 |
p. 20-33
|
article
|
| 4 |
Anti-B-Cell Therapies in Autoimmune Neurological Diseases: Rationale and Efficacy Trials
|
Alexopoulos, Harry
|
|
|
13 |
1 |
p. 20-33
|
article
|
| 5 |
Antibody-Mediated Autoimmune Encephalopathies and Immunotherapies
|
Gastaldi, Matteo
|
|
2015
|
13 |
1 |
p. 147-162
|
article
|
| 6 |
Antibody-Mediated Autoimmune Encephalopathies and Immunotherapies
|
Gastaldi, Matteo
|
|
|
13 |
1 |
p. 147-162
|
article
|
| 7 |
Chronic Treatment with the AMPK Agonist AICAR Prevents Skeletal Muscle Pathology but Fails to Improve Clinical Outcome in a Mouse Model of Severe Spinal Muscular Atrophy
|
Cerveró, Clàudia
|
|
2015
|
13 |
1 |
p. 198-216
|
article
|
| 8 |
Chronic Treatment with the AMPK Agonist AICAR Prevents Skeletal Muscle Pathology but Fails to Improve Clinical Outcome in a Mouse Model of Severe Spinal Muscular Atrophy
|
Cerveró, Clàudia
|
|
|
13 |
1 |
p. 198-216
|
article
|
| 9 |
Current Treatment, Emerging Translational Therapies, and New Therapeutic Targets for Autoimmune Myasthenia Gravis
|
Guptill, Jeffrey T.
|
|
2015
|
13 |
1 |
p. 118-131
|
article
|
| 10 |
Current Treatment, Emerging Translational Therapies, and New Therapeutic Targets for Autoimmune Myasthenia Gravis
|
Guptill, Jeffrey T.
|
|
|
13 |
1 |
p. 118-131
|
article
|
| 11 |
Efficacy of Intravenous Immunoglobulin in Neurological Diseases
|
Lünemann, Jan D.
|
|
2015
|
13 |
1 |
p. 34-46
|
article
|
| 12 |
Efficacy of Intravenous Immunoglobulin in Neurological Diseases
|
Lünemann, Jan D.
|
|
|
13 |
1 |
p. 34-46
|
article
|
| 13 |
Erratum to: Interaction of Paroxetine with Mitochondrial Proteins Mediates Neuroprotection
|
Steiner, Joseph P.
|
|
2015
|
13 |
1 |
p. 237
|
article
|
| 14 |
Erratum to: Interaction of Paroxetine with Mitochondrial Proteins Mediates Neuroprotection
|
Steiner, Joseph P.
|
|
|
13 |
1 |
p. 237
|
article
|
| 15 |
Erratum to: Neuronal Glutathione Content and Antioxidant Capacity can be Normalized In Situ by N-acetyl Cysteine Concentrations Attained in Human Cerebrospinal Fluid
|
Reyes, Reno C.
|
|
2015
|
13 |
1 |
p. 239
|
article
|
| 16 |
Erratum to: Neuronal Glutathione Content and Antioxidant Capacity can be Normalized In Situ by N-acetyl Cysteine Concentrations Attained in Human Cerebrospinal Fluid
|
Reyes, Reno C.
|
|
|
13 |
1 |
p. 239
|
article
|
| 17 |
Erratum to: Remarkable Phenytoin Sensitivity in 4 Children with SCN8A-related Epilepsy: A Molecular Neuropharmacological Approach
|
Boerma, Ragna S.
|
|
2015
|
13 |
1 |
p. 238
|
article
|
| 18 |
Erratum to: Remarkable Phenytoin Sensitivity in 4 Children with SCN8A-related Epilepsy: A Molecular Neuropharmacological Approach
|
Boerma, Ragna S.
|
|
|
13 |
1 |
p. 238
|
article
|
| 19 |
Immunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders
|
Valera, Elvira
|
|
2015
|
13 |
1 |
p. 179-189
|
article
|
| 20 |
Immunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders
|
Valera, Elvira
|
|
|
13 |
1 |
p. 179-189
|
article
|
| 21 |
Immunotherapies for Immune-Mediated Myopathies: A Current Perspective
|
Needham, Merrilee
|
|
2015
|
13 |
1 |
p. 132-146
|
article
|
| 22 |
Immunotherapies for Immune-Mediated Myopathies: A Current Perspective
|
Needham, Merrilee
|
|
|
13 |
1 |
p. 132-146
|
article
|
| 23 |
Immunotherapies for Neurological Manifestations in the Context of Systemic Autoimmunity
|
Kampylafka, Eleni I.
|
|
2015
|
13 |
1 |
p. 163-178
|
article
|
| 24 |
Immunotherapies for Neurological Manifestations in the Context of Systemic Autoimmunity
|
Kampylafka, Eleni I.
|
|
|
13 |
1 |
p. 163-178
|
article
|
| 25 |
Immunotherapy in Peripheral Neuropathies
|
Léger, Jean-Marc
|
|
2015
|
13 |
1 |
p. 96-107
|
article
|
| 26 |
Immunotherapy in Peripheral Neuropathies
|
Léger, Jean-Marc
|
|
|
13 |
1 |
p. 96-107
|
article
|
| 27 |
Immunotherapy Prospects for Painful Small-fiber Sensory Neuropathies and Ganglionopathies
|
Oaklander, Anne Louise
|
|
2015
|
13 |
1 |
p. 108-117
|
article
|
| 28 |
Immunotherapy Prospects for Painful Small-fiber Sensory Neuropathies and Ganglionopathies
|
Oaklander, Anne Louise
|
|
|
13 |
1 |
p. 108-117
|
article
|
| 29 |
Improved Treatment Efficacy of Antiangiogenic Therapy when Combined with Picornavirus Vaccination in the GL261 Glioma Model
|
Renner, Danielle N.
|
|
2015
|
13 |
1 |
p. 226-236
|
article
|
| 30 |
Improved Treatment Efficacy of Antiangiogenic Therapy when Combined with Picornavirus Vaccination in the GL261 Glioma Model
|
Renner, Danielle N.
|
|
|
13 |
1 |
p. 226-236
|
article
|
| 31 |
Neuro-Immunotherapies: A 30-year Retrospective of an Overwhelming Success and a Brighter Future
|
Dalakas, Marinos C.
|
|
2015
|
13 |
1 |
p. 1-3
|
article
|
| 32 |
Neuro-Immunotherapies: A 30-year Retrospective of an Overwhelming Success and a Brighter Future
|
Dalakas, Marinos C.
|
|
|
13 |
1 |
p. 1-3
|
article
|
| 33 |
Neuroimmunotherapies Targeting T Cells: From Pathophysiology to Therapeutic Applications
|
Bittner, Stefan
|
|
2015
|
13 |
1 |
p. 4-19
|
article
|
| 34 |
Neuroimmunotherapies Targeting T Cells: From Pathophysiology to Therapeutic Applications
|
Bittner, Stefan
|
|
|
13 |
1 |
p. 4-19
|
article
|
| 35 |
Neuronal Glutathione Content and Antioxidant Capacity can be Normalized In Situ by N-acetyl Cysteine Concentrations Attained in Human Cerebrospinal Fluid
|
Reyes, Reno C.
|
|
2015
|
13 |
1 |
p. 217-225
|
article
|
| 36 |
Neuronal Glutathione Content and Antioxidant Capacity can be Normalized In Situ by N-acetyl Cysteine Concentrations Attained in Human Cerebrospinal Fluid
|
Reyes, Reno C.
|
|
|
13 |
1 |
p. 217-225
|
article
|
| 37 |
Precision Medicine: SCN8A Encephalopathy Treated with Sodium Channel Blockers
|
Møller, Rikke S.
|
|
2015
|
13 |
1 |
p. 190-191
|
article
|
| 38 |
Precision Medicine: SCN8A Encephalopathy Treated with Sodium Channel Blockers
|
Møller, Rikke S.
|
|
|
13 |
1 |
p. 190-191
|
article
|
| 39 |
Present and Future Therapies in Neuromyelitis Optica Spectrum Disorders
|
Kleiter, Ingo
|
|
2015
|
13 |
1 |
p. 70-83
|
article
|
| 40 |
Present and Future Therapies in Neuromyelitis Optica Spectrum Disorders
|
Kleiter, Ingo
|
|
|
13 |
1 |
p. 70-83
|
article
|
| 41 |
PROGRAM
|
|
|
2015
|
13 |
1 |
p. 240-260
|
article
|
| 42 |
PROGRAM
|
|
|
|
13 |
1 |
p. 240-260
|
article
|
| 43 |
Remarkable Phenytoin Sensitivity in 4 Children with SCN8A-related Epilepsy: A Molecular Neuropharmacological Approach
|
Boerma, Ragna S.
|
|
2015
|
13 |
1 |
p. 192-197
|
article
|
| 44 |
Remarkable Phenytoin Sensitivity in 4 Children with SCN8A-related Epilepsy: A Molecular Neuropharmacological Approach
|
Boerma, Ragna S.
|
|
|
13 |
1 |
p. 192-197
|
article
|
| 45 |
Therapeutic Advances and Future Prospects in Progressive Forms of Multiple Sclerosis
|
Shirani, Afsaneh
|
|
2015
|
13 |
1 |
p. 58-69
|
article
|
| 46 |
Therapeutic Advances and Future Prospects in Progressive Forms of Multiple Sclerosis
|
Shirani, Afsaneh
|
|
|
13 |
1 |
p. 58-69
|
article
|
| 47 |
Therapeutic Approach to the Management of Pediatric Demyelinating Disease: Multiple Sclerosis and Acute Disseminated Encephalomyelitis
|
Brenton, J. Nicholas
|
|
2015
|
13 |
1 |
p. 84-95
|
article
|
| 48 |
Therapeutic Approach to the Management of Pediatric Demyelinating Disease: Multiple Sclerosis and Acute Disseminated Encephalomyelitis
|
Brenton, J. Nicholas
|
|
|
13 |
1 |
p. 84-95
|
article
|
Journal description